Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HORIZON-MISS-2021-CANCER-02-03 | Other Grant/Funding Number | European Comission |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Clinic of Barcelona | OTHER |
Not provided
Not provided
Not provided
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults. This database will be used to perform survival analysis and evaluate sentinel lymph node (SLNB) positivity in CAYA. The secondary objectives to be met are the following:
Precis-Mel 1 is a unicentric observational study using retrospectively collected data. The proposed procedure is to start using data including demographic and family data, genetic data, medical procedures and cancer treatment, cutaneous biopsy, etc. to build a multidimensional dataset and apply AI algorithms that can produce survival curves and sentinel lymph node (SLNB) positivity in CAYA. The approach to be used is presented in the following sub-sections:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Melanoma patients | The training dataset will consist of 6000 adult melanoma patients while the adaptation dataset for children, adolescents and young adults (CAYA) will be of N = 120. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gradient Boosting Survival Analysis (GBSA), | Other | It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient prognosis curves | The main outcome of the study will be to obtain prognosis indicators, mainly survival curves and sentinel lymph node (SLNB) positivity, by training artificial intelligence-based models using tabular clinical data in children, adolescents and young adults (CAYA). | 24 months |
Not provided
Not provided
Inclusion Criteria:
- Melanoma patients of any age with histopathological confirmed melanoma
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Review and/or analysis of pre-existing medical records, biological samples and data collected from patients that have been visited at our hospital.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Susana Puig Sardà, MD, PhD | Contact | +34932275400 | spuig@clinic.cat | |
| Adrián López Canosa, PhD | Contact | lopez64@recerca.clinic.cat |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Clínic de Barcelona (Dermatology service) | Recruiting | Barcelona | Catalonia | 08036 | Spain |
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| D018326 | Nevi and Melanomas |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Concordance index | Other | The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features. |
|
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |